Nordic Science Investments

Nordic Science Investments is a venture capital investment firm based in Helsinki, Finland, established in 2024. The firm is committed to transforming groundbreaking scientific discoveries into successful companies by bridging the gap between academia and business. It invests in science-based startups and university spinouts that tackle global challenges, with a particular emphasis on deeptech, healthtech, and life sciences. By supporting visionary founders from the New Nordics, Nordic Science Investments fosters innovation and growth, guiding companies from pre-seed through to selected Series A stages.

Matti Hautsalo

Founding Partner

9 past transactions

Solid IO

Pre Seed Round in 2025
Solid IO is a biotechnology company specializing in organ-on-chip technology for oncology. It replicates the tumor microenvironment to provide real-time, patient-specific insights, enabling clinicians to make precise treatment decisions and accelerating immuno-oncology drug development.

Phenaros Pharmaceuticals

Pre Seed Round in 2025
Phenaros Pharmaceuticals is a Swedish spin-off drug discovery company from Uppsala University. We employ phenomics (large-scale cell morphological profiling) in conjunction with automation and AI to discover and repurpose medications for uncommon diseases. Aside from developing an in-house drug discovery pipeline, we also form collaborations to provide access to our discovery platform.

Acouspin

Pre Seed Round in 2025
Acouspin is a technology company that specializes in AI-driven, ultrasonic-enhanced systems for efficient and flexible nanofiber production. Their innovative solution enables manufacturers to achieve precision in nanofiber production without requiring specific expertise. The technology addresses common challenges such as needle clogs, allows real-time adjustments to fiber diameters, and simplifies the manufacturing process, making it more accessible and efficient. This transformation opens up new possibilities for large-scale applications across various industries.

PrecisionPhage

Seed Round in 2024
PrecisionPhage, based in Jyvaskyla, Finland, is a biotechnology company focused on bacteriophage technologies. It provides an online phage genome analysis tool and services including bioinformatic analyses, bacteriophage licensing, and laboratory services. These offerings enable healthcare firms to perform genome assembly, analysis, and comparison, as well as facilitate drug development research.

NADMED

Series A in 2024
NADMED develops NAD measurement technology designed to quantify all four NAD forms and glutathione. Its metabolite extraction system uses a nondestructive extraction method and colorimetric quantification to enable precise analysis across diverse biological samples. The technology supports research and clinical applications by providing measuring kits for laboratories and laboratory services, with use cases spanning cells, liver, brain, muscle, and blood from human or animal origin. NADMED aims to support researchers and clinicians in studying NAD metabolism and redox biology through accessible, reliable measurement tools.

RNatives

Pre Seed Round in 2024
RNatives is a biotechnology company dedicated to the development of innovative RNA-based therapies. The firm specializes in RNA activation, particularly in up-regulating the VEGFA gene, which is crucial for addressing cardiovascular diseases such as myocardial ischemia and peripheral artery disease. RNatives employs advanced research and development methodologies to create novel therapeutic options aimed at conditions with significant unmet medical needs. With a team of skilled professionals, the company is committed to advancing its lead programs and pushing the boundaries of biotechnology to enhance patient outcomes. Through its focus on the unique biology of nuclear microRNAs, RNatives seeks to streamline the discovery and development of RNA activation drugs for various medical indications.

AIATELLA

Pre Seed Round in 2024
AIATELLA is a company focused on revolutionizing cardiovascular diagnostics by utilizing artificial intelligence to automate the quantification, detection, and interpretation of medical images. Their advanced technology caters to various imaging modalities, aiming to enhance efficiency and ensure standardized analysis while supporting precision medicine. In response to the global challenges posed by a shortage of radiologists and the increasing prevalence of cardiovascular diseases, AIATELLA develops cloud-based medical software that equips healthcare professionals with AI systems designed to accurately detect and diagnose these conditions. By providing innovative tools, the company seeks to improve diagnostic accuracy and ultimately enhance patient outcomes in the healthcare sector.

Perfat Technologies

Seed Round in 2024
Perfat Technologies is a health-focused technology company that specializes in developing innovative fat-management applications using healthy vegetable oils. The company utilizes advanced oleogel and ultrasound technologies to create plant-based fats and alternative protein products, optimizing bioprocesses for enhanced research and development. This approach helps lower production costs and improve sustainability in food processing. By enhancing the techno-functionalities of oils such as rapeseed and sunflower, Perfat Technologies enables a broader application of these healthier alternatives in the food industry, promoting better choices for consumers.

RNatives

RNatives is a biotechnology company dedicated to the development of innovative RNA-based therapies. The firm specializes in RNA activation, particularly in up-regulating the VEGFA gene, which is crucial for addressing cardiovascular diseases such as myocardial ischemia and peripheral artery disease. RNatives employs advanced research and development methodologies to create novel therapeutic options aimed at conditions with significant unmet medical needs. With a team of skilled professionals, the company is committed to advancing its lead programs and pushing the boundaries of biotechnology to enhance patient outcomes. Through its focus on the unique biology of nuclear microRNAs, RNatives seeks to streamline the discovery and development of RNA activation drugs for various medical indications.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.